OrthoLite Vietnam Awarded Second Consecutive Best Companies to Work for in Asia Award
Organized and presented by HR Asia, the Best Companies to Work for in Asia Awards evaluates and honors organizations with best practices in human resources, high levels of employee engagement and excellent workplace cultures.
OrthoLite Vietnam (OVN) successfully completed multiple rigorous assessments conducted across all levels of company leadership, exceeding the comprehensive criteria required to achieve the highest distinction—first place. HR Asia's evaluation further highlighted OrthoLite Vietnam's outstanding performance, with scores significantly surpassing the market average.
"We couldn't be prouder of our exceptional team and leadership in Vietnam," said Glenn Barrett, founder and CEO of OrthoLite. "Their unwavering dedication, proactive mindset, and strong spirit of collaboration are a direct reflection of the unique culture we've built—one that is integral to our success. It's this culture that empowers our teams to consistently deliver the highest quality insole solutions to our global brand partners every day."
The OVN team comprises over 1,000 employees who work in OrthoLite's state-of-the-art facility in Ho Chi Minh City, Vietnam. OVN's automation, growing lean lines and attention to the company's best manufacturing for less-impactful manufacturing, combine to make it a leading manufacturing facility for OrthoLite.
"We are truly honored to receive this award for the second year in a row and to be recognized for the strength of our incredible team and company culture," said Mark Coffield, Country Manager for OrthoLite Vietnam. "Our exceptional team has a collaborative spirit and dedication that are unmatched and are at the heart of every partnership we build with OrthoLite brand partners."
OVN is one of six vertically-integrated global manufacturing facilities owned by OrthoLite, all of which work together to bring an unmatched level of consistency, transparency and best practices to the brand's 550-plus global brand partners.
Recently OVN's Higg Index score was released, which showed the facility and team achieved an overall verified score of 90-percent.
"This is all due to the exceptional leadership and dedication of Jenny Le, Human Resource Director at OVN, who has led our HR program for over six years," Coffield noted. "It's also due to our dedicated OVN team, who work daily toward our goal of achieving sustainability through environmental management, energy, water use, wastewater management, waste management, air quality and chemical management."
For additional information on OrthoLite, please visit ortholite.com.
About OrthoLite®
OrthoLite is the world's leading supplier of open-cell foam technology found in more than 550 footwear brands across all categories of footwear and is the first name in comfort and performance foams. OrthoLite has a stalwart commitment to an ongoing journey toward producing excellence with less-impactful manufacturing practices. The company also has a long-standing history of meaningful partnerships and sponsorships that demonstrate a dedicated commitment to supporting its customers, consumers, brand partners and the footwear industry. OrthoLite is the Official Insole sponsor of the New York Yankees, supporter of Textile Exchange, and is a founding supporter of the Two Ten Foundation. Stay up to date with company news by visiting OrthoLite.com and following OrthoLite on Facebook, Instagram, Twitter and LinkedIn. To learn more about the benefits of OrthoLite, visit www.ortholite.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250820914941/en/
Contacts
Media Contact: Verde Brand CommunicationsJulie Evans970.946.0856julie@verdepr.com Media Assets
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM
Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech startup pioneering next-generation bioconjugation solutions, has been named the winner of the 2025 Golden Ticket Programme in Singapore. The award is part of a joint programme by Amgen, a U.S.-based leader in biologic medicines and NSG BioLabs, Singapore's leading provider of biotechnology co-working laboratories and offices. Now in its fourth year, the Golden Ticket Programme supports promising biotech startups by providing infrastructure, mentorship, and resources to advance scientific progress and talent development in accelerating the development of new therapies. As this year's awardee, Singzyme will receive a one-year residency at NSG BioLabs, along with access to certified BSL-2 lab facilities and networking opportunities through Amgen's community of scientific and business leaders. Singzyme was selected from a competitive pool of six finalists following an interactive pitch session reviewed by Amgen's internal scientific committee. The startup stood out for its proprietary Peptide Asparaginyl Ligase (PAL) platform, a novel site-specific conjugation technology that addresses key challenges in the manufacturing of antibody-drug conjugates (ADCs) and other complex biologics. The platform holds strong potential for enabling safer, more precise, and efficient production of next-generation targeted therapies. "Singzyme's novel platform reflects the strong scientific thinking and innovation emerging from Singapore's biotech sector," said Dr Alan Russell, Vice President for Research Biologics at Amgen. "It's encouraging to see creative approaches to longstanding challenges in bioconjugation, and we're pleased to be part of an initiative that helps spotlight and connect promising science with broader networks in the industry that aligns with Amgen's mission to deliver impactful therapies to serve patients." Ms Daphne Teo, CEO and Founder of NSG BioLabs, added, "The Golden Ticket Programme provides a valuable stepping stone for biotech startups at critical stages of their journey. As Singapore's life sciences community continues to expand, it's exciting to support companies like Singzyme as they bring their ideas to life and move closer to the clinic in Singapore's growing vibrant biotech industry." Mr Abbas Sahili, Chief Technology Officer, inventor and founding team member of Singzyme, said, "This award validates the transformative potential of Singzyme's peptide ligation technology to enable the next generation of precision medicines. The Golden Ticket is a significant recognition of our PAL platform's ability to address critical unmet needs in biologics development - not only in oncology, but across diverse modalities and disease areas." Mr Wee Kiat Tan, CEO of Singzyme, said, "With this support, we are committed to advancing our platform toward clinical applications in oncology and beyond. Through this collaboration, we will continue to strengthen our capabilities and accelerate the delivery of impactful therapies to patients worldwide." Singzyme joins a growing list of previous Golden Ticket recipients in Singapore, including Albatroz Therapeutics, VerImmune, and PairX Bio. These companies have leveraged the programme's access and visibility to further their research, raise funding, and expand partnerships. Albatroz secured US$3 million in seed funding to advance its drug development programmes, while VerImmune's recent closure of the first half of its Pre-Series A round reflects strong confidence in its platform and trajectory. Unlocking Biotech Growth Through Cross-Sector Collaboration Accelerating biotech startups takes more than breakthrough science, it requires the right mix of mentorship, infrastructure, and collaboration. This was the key message shared at a panel discussion held at the award ceremony, titled "Powering Biotech Breakthroughs: Scaling Science Through Cross-Sector Collaboration." Speakers from Amgen, ClavystBio, and the Singapore Economic Development Board (EDB) discussed how cross-sector collaboration is helping startups progress from scientific concepts to real-world applications. The discussion emphasized the importance of a dynamic ecosystem – one that offers shared infrastructure, strong talent pipelines, and access to mentorship – to support biotech ventures and enable researchers and entrepreneurs to grow and scale globally. "We are growing Singapore's biotech leadership via three key drivers – access to capital, a strong talent pool, and strategic partnerships," said Mr Chen Pengfei, Vice President for Healthcare of EDB. "Beyond a strong scientific community, a vibrant entrepreneurship ecosystem is critical to bringing innovations to market. We hope to forge more collaborations with key stakeholders including academic and biotech companies, to unlock greater growth opportunities from Singapore." For more information on Golden Ticket Programme, visit About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit and follow Amgen on X, LinkedIn, Instagram, TikTok, YouTube and Threads. About NSG BioLabs Founded with a focus on supporting biotech innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiency, the expertise of world-class teams and global networks to assist life sciences companies. The conducive R&D environment contains fully-equipped, certified BSL-2 laboratory and office infrastructure across 70,000 sq ft within Singapore's biomedical science clusters, Biopolis and Singapore Science Park. By providing access to high-quality infrastructure, its extensive partner network, community, and value-add benefits, NSG BioLabs ensures that companies, ranging from emerging biotech startups to multinational companies, can rapidly and efficiently execute on their cutting-edge research and development ecosystem in Singapore, leading to the innovation of revolutionary technologies and products that translate into breakthrough biotech ventures and impact for patients. For more information, visit About Singzyme Singzyme is a Singapore-based biotechnology company pioneering next-generation bioconjugation solutions for the manufacturing of antibody-drug conjugates (ADCs) and other complex biologics. Its proprietary Peptide Asparaginyl Ligase (PAL) based conjugation platform enables highly precise, efficient, and scalable site-specific conjugation of payloads to antibodies and other proteins. By combining breakthrough enzymatic technology with deep expertise in protein engineering, Singzyme empowers partners to accelerate the development of safer, more effective targeted therapies. For more information visit View original content to download multimedia: SOURCE Amgen
Yahoo
24 minutes ago
- Yahoo
Bilibili Inc. Announces Second Quarter 2025 Financial Results
SHANGHAI, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Bilibili Inc. ('Bilibili' or the 'Company') (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights: Total net revenues were RMB7.34 billion (US$1,024.3 million), representing an increase of 20% year over year. Advertising revenues were RMB2.45 billion (US$341.9 million), representing an increase of 20% year over year. Mobile games revenues were RMB1.61 billion (US$225.1 million), representing an increase of 60% year over year. Gross profit was RMB2.68 billion (US$373.5 million), representing an increase of 46% year over year. Gross profit margin reached 36.5%, improving from 29.9% in the same period of 2024. Net profit was RMB218.3 million (US$30.5 million), compared with a net loss of RMB608.1 million in the same period of 2024. Adjusted net profit1 was RMB561.3 million (US$78.4 million), compared with an adjusted net loss of RMB271.0 million in the same period of 2024. Net cash provided by operating activities was RMB1.99 billion (US$277.7 million), compared with RMB1.75 billion in the same period of 2024. Average daily active users (DAUs) were 109.4 million, representing an increase of 7% year over year. 'We furthered our healthy momentum in the second quarter with solid financial results and strong community engagement,' said Mr. Rui Chen, Chairman and Chief Executive Officer of Bilibili. 'In the second quarter, DAUs grew by 7%, monthly active users by 8%, and monthly paying users by 9%, year over year. Average daily time spent was 105 minutes, up 6 minutes compared to a year ago, demonstrating our growing influence among China's young generations. This summer, we welcomed more than 400,000 people to join our flagship offline events Bilibili World and Bilibili Marco Link, making the three-day event one of the largest offline animation expos in China. The enthusiastic turnout underscores the vibrancy of our brand and the strength of our community, highlighting the enormous potential of our young user base. Looking ahead, we will stay focused on delivering premium content experiences that resonate with young audiences, fueling user growth and deepening engagement, while continuing to unlock the full commercial potential of our vibrant ecosystem.' Mr. Sam Fan, Chief Financial Officer of Bilibili, said, 'In the second quarter, our total net revenues grew by 20% year over year to RMB7.34 billion. The growth was mainly attributable to strong growth in both advertising and games businesses, which rose by 20% and 60% year over year, respectively. Gross profit improved by 46% year over year, with gross profit margin rising to 36.5%, up from 29.9% in the same period last year. These increases fueled improvements in our profitability, with net profit and adjusted net profit reaching RMB218.3 million and RMB561.3 million, respectively. We also generated a robust net operating cashflow of RMB1.99 billion in the quarter. In the second quarter, we completed the repurchase of 5,588,140 Class Z ordinary shares for an aggregate amount of HK$782.9 million. Going forward, we will focus on maintaining efficient, sustainable and profitable operations that create value for all of our stakeholders.' Second Quarter 2025 Financial Results Total net revenues. Total net revenues were RMB7.34 billion (US$1,024.3 million), representing an increase of 20% from the same period of 2024. Value-added services (VAS). Revenues from VAS were RMB2.84 billion (US$396.0 million), representing an increase of 11% from the same period of 2024, mainly attributable to increased revenues from live broadcasting and other value-added services. Advertising. Revenues from advertising were RMB2.45 billion (US$341.9 million), representing an increase of 20% from the same period of 2024, mainly attributable to strong revenue growth in performance-based advertising. Mobile games. Revenues from mobile games were RMB1.61 billion (US$225.1 million), representing an increase of 60% from the same period of 2024, mainly attributable to the strong performance of the Company's exclusively licensed game, San Guo: Mou Ding Tian Xia. IP derivatives and others. Revenues from IP derivatives and others were RMB439.9 million (US$61.4 million), representing a decrease of 15% from the same period of 2024. Cost of revenues. Cost of revenues was RMB4.66 billion (US$650.8 million), representing an increase of 9% from the same period of 2024. The increase was mainly due to higher revenue sharing costs and was partially offset by lower content costs. Revenue-sharing costs, a key component of cost of revenues, were RMB2.97 billion (US$414.0 million), representing an increase of 19% from the same period of 2024, and the increase was in line with the increase of our revenue growth. Gross profit. Gross profit was RMB2.68 billion (US$373.5 million), representing an increase of 46% from the same period of 2024, mainly attributable to the growth in total net revenues and relatively stable costs related to platform operations as the Company enhanced its monetization efficiency. Total operating expenses. Total operating expenses were RMB2.42 billion (US$338.4 million), which remained stable compared with the same period of 2024. Sales and marketing expenses. Sales and marketing expenses were RMB1.05 billion (US$146.3 million), representing an increase of 1% from the same period of 2024. General and administrative expenses. General and administrative expenses were RMB509.6 million (US$71.1 million), representing an increase of 4% compared with the same period of 2024. Research and development expenses. Research and development expenses were RMB866.4 million (US$120.9 million), representing a 3% decrease from the same period of 2024. Profit/(loss) from operations. Profit from operations was RMB251.6 million (US$35.1 million), compared with a loss of RMB585.1 million from the same period of 2024. Adjusted profit/(loss) from operations1. Adjusted profit from operations was RMB573.2 million (US$80.0 million), compared with an adjusted loss from operations of RMB283.9 million from the same period of 2024. Total other (expenses)/income, net. Total other expenses were RMB7.0 million (US$1.0 million), compared with total other expenses of RMB29.2 million in the same period of 2024. Income tax (expense)/benefit. Income tax expense was RMB26.4 million (US$3.7 million), compared with income tax benefit of RMB6.2 million in the same period of 2024. Net profit/(loss). Net profit was RMB218.3 million (US$30.5 million), compared with a net loss of RMB608.1 million in the same period of 2024. Adjusted net profit/(loss)1. Adjusted net profit was RMB561.3 million (US$78.4 million), compared with an adjusted net loss of RMB271.0 million in the same period of 2024. Basic and diluted EPS and adjusted basic and diluted EPS1. Basic and diluted earnings per share were RMB0.52 (US$0.07) and RMB0.51 (US$0.07), compared with basic and diluted net loss per share of RMB1.46 each in the same period of 2024. Adjusted basic and diluted net earnings per share were RMB1.34 (US$0.19) and RMB1.29 (US$0.18), respectively, compared with an adjusted basic and diluted net loss per share of RMB0.65 each in the same period of 2024. Net cash provided by operating activities. Net cash provided by operating activities was RMB1.99 billion (US$277.7 million), compared with RMB1.75 billion in the same period of 2024. Cash and cash equivalents, time deposits and short-term investments. As of June 30, 2025, the Company had cash and cash equivalents, time deposits and short-term investments of RMB22.29 billion (US$3.11 billion). Recent Developments In May 2025, the Company completed an offering of US$690.0 million in aggregate principal amount of convertible senior notes due 2030 (the 'Notes Offering'), with an interest rate of 0.625% per year. The Company planned to use the net proceeds from the Notes Offering for enhancing its content ecosystem, improving its overall monetization efficiency, funding the Concurrent Repurchase (as defined below), funding future repurchases (from time to time) under its share repurchase program, and for other general corporate purposes. The Company raised total net proceeds of approximately US$678.1 million from the Notes Offering, after deducting the initial purchasers' commissions and expenses. The Company also concurrently repurchased 5,588,140 Class Z ordinary shares (each represented by one ADS) for an aggregate amount of HK$782.9 million (US$100.0 million as translated on the date of the Notes Offering) (the 'Concurrent Repurchase') pursuant to its existing share repurchase program. All of the Class Z ordinary shares repurchased under the Concurrent Repurchase have been cancelled as of the end of the second quarter of 2025. Pursuant to its US$200 million share repurchase program which was approved by the Board in November 2024, the Company had repurchased a total of 6.4 million of its listed securities for a total cost of US$116.4 million, with the remaining amount being approximately US$83.6 million as of June 30, 2025. 1 Adjusted profit/(loss) from operations, adjusted net profit/(loss), and adjusted basic and diluted EPS are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section 'Use of Non-GAAP Financial Measures' and the table captioned 'Unaudited Reconciliations of GAAP and Non-GAAP Results.' Conference Call The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 21, 2025 (8:00 PM Beijing/Hong Kong Time on August 21, 2025). Details for the conference call are as follows: Event Title: Bilibili Inc. Second Quarter 2025 Earnings Conference Call Registration Link: All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers and a personal PIN, which will be used to join the conference call. Additionally, a live webcast of the conference call will be available on the Company's investor relations website at and a replay of the webcast will be available following the session. About Bilibili Inc. Bilibili is an iconic brand and a leading video community with a mission to enrich the everyday lives of young generations in China. Bilibili offers a wide array of video-based content with 'All the Videos You Like' as its value proposition. Bilibili builds its community around aspiring users, high-quality content, talented content creators and the strong emotional bonds among them. Bilibili pioneered the 'bullet chatting' feature, a live comment function that has transformed users' viewing experience by displaying the thoughts and feelings of audience members viewing the same video. The Company has now become the welcoming home of diverse interests among young generations in China and a frontier for promoting Chinese culture around the world. For more information, please visit: Use of Non-GAAP Financial Measures The Company uses non-GAAP measures, such as adjusted profit/(loss) from operations, adjusted net profit/(loss), adjusted net profit/(loss) per share and per ADS, basic and diluted and adjusted net profit/(loss) attributable to the Bilibili Inc.'s shareholders in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business by excluding the impact of share-based compensation expenses, amortization expense related to intangible assets acquired through business acquisitions, income tax related to intangible assets acquired through business acquisitions, gain/loss on fair value change in investments in publicly traded companies, and gain/loss on repurchase of convertible senior notes. The Company believes that the non-GAAP financial measures provide useful information about the Company's results of operations, enhance the overall understanding of the Company's past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP and therefore, may not be comparable to similar measures presented by other companies. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company's operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance. For more information on the non-GAAP financial measures, please see the table captioned 'Unaudited Reconciliations of GAAP and Non-GAAP Results.' Exchange Rate Information This announcement contains translations of certain RMB amounts into U.S. dollars ('US$') at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB7.1636 to US$1.00, the exchange rate on June 30, 2025 set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or US$ amounts referred to could be converted into US$ or RMB, as the case may be, at any particular rate or at all. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident,' 'potential,' 'continue,' or other similar expressions. Among other things, outlook and quotations from management in this announcement, as well as Bilibili's strategic and operational plans, contain forward-looking statements. Bilibili may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its interim and annual reports to shareholders, in announcements, circulars or other publications made on the website of The Stock Exchange of Hong Kong Limited (the 'Hong Kong Stock Exchange'), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Bilibili's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: results of operations, financial condition, and stock price; Bilibili's strategies; Bilibili's future business development, financial condition and results of operations; Bilibili's ability to retain and increase the number of users, members and advertising customers, provide quality content, products and services, and expand its product and service offerings; competition in the online entertainment industry; Bilibili's ability to maintain its culture and brand image within its addressable user communities; Bilibili's ability to manage its costs and expenses; PRC governmental policies and regulations relating to the online entertainment industry, general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission and the Hong Kong Stock Exchange. All information provided in this announcement and in the attachments is as of the date of the announcement, and the Company undertakes no duty to update such information, except as required under applicable law. For investor and media inquiries, please contact: In China: Bilibili YangTel: +86-21-2509-9255 Ext. 8523E-mail: ir@ Piacente Financial Communications Helen WuTel: +86-10-6508-0677E-mail: bilibili@ In the United States: Piacente Financial Communications Brandi PiacenteTel: +1-212-481-2050E-mail: bilibili@ Condensed Consolidated Statements of Operations(All amounts in thousands, except for share and per share data) For the Three Months Ended For the Six Months Ended June30, March31, June30, June30, June30, 2024 2025 2025 2024 2025 RMB RMB RMB RMB RMB Net revenues: Value-added services (VAS) 2,565,888 2,807,340 2,836,596 5,094,797 5,643,936 Advertising 2,037,491 1,997,635 2,448,888 3,706,075 4,446,523 Mobile games 1,007,367 1,731,155 1,612,333 1,990,177 3,343,488 IP derivatives and others 516,398 467,118 439,873 1,000,695 906,991 Total net revenues 6,127,144 7,003,248 7,337,690 11,791,744 14,340,938 Cost of revenues (4,293,943 ) (4,464,150 ) (4,661,844 ) (8,353,183 ) (9,125,994 ) Gross profit 1,833,201 2,539,098 2,675,846 3,438,561 5,214,944 Operating expenses: Sales and marketing expenses (1,035,596 ) (1,166,975 ) (1,048,189 ) (1,962,655 ) (2,215,164 ) General and administrative expenses (488,039 ) (515,638 ) (509,631 ) (1,019,816 ) (1,025,269 ) Research and development expenses (894,701 ) (841,477 ) (866,414 ) (1,859,821 ) (1,707,891 ) Total operating expenses (2,418,336 ) (2,524,090 ) (2,424,234 ) (4,842,292 ) (4,948,324 ) (Loss)/profit from operations (585,135 ) 15,008 251,612 (1,403,731 ) 266,620 Other (expenses)/income: Investment loss, net (including impairments) (94,684 ) (62,203 ) (56,875 ) (115,933 ) (119,078 ) Interest income 100,344 94,173 101,639 233,551 195,812 Interest expense (19,809 ) (32,571 ) (35,506 ) (51,383 ) (68,077 ) Exchange losses (15,275 ) (11,659 ) (11,710 ) (73,335 ) (23,369 ) Debt extinguishment loss - - (2 ) (20,980 ) (2 ) Others, net 256 (1,837 ) (4,518 ) 54,439 (6,355 ) Total other (expenses)/income, net (29,168 ) (14,097 ) (6,972 ) 26,359 (21,069 ) (Loss)/profit before income tax (614,303 ) 911 244,640 (1,377,372 ) 245,551 Income tax benefit/(expense) 6,154 (11,588 ) (26,357 ) 4,592 (37,945 ) Net (loss)/profit (608,149 ) (10,677 ) 218,283 (1,372,780 ) 207,606 Net (profit)/loss attributable to noncontrolling interests (551 ) 1,575 719 15,535 2,294 Net (loss)/profit attributable to the Bilibili Inc.'s shareholders (608,700 ) (9,102 ) 219,002 (1,357,245 ) 209,900 Net (loss)/profit per share, basic (1.46 ) (0.02 ) 0.52 (3.26 ) 0.50 Net (loss)/profit per ADS, basic (1.46 ) (0.02 ) 0.52 (3.26 ) 0.50 Net (loss)/profit per share, diluted (1.46 ) (0.02 ) 0.51 (3.26 ) 0.49 Net (loss)/profit per ADS, diluted (1.46 ) (0.02 ) 0.51 (3.26 ) 0.49 Weighted average number of ordinary shares, basic 416,287,273 420,086,397 419,443,582 415,780,807 419,763,214 Weighted average number of ADS, basic 416,287,273 420,086,397 419,443,582 415,780,807 419,763,214 Weighted average number of ordinary shares, diluted 416,287,273 420,086,397 437,370,780 415,780,807 431,601,628 Weighted average number of ADS, diluted 416,287,273 420,086,397 437,370,780 415,780,807 431,601,628 The accompanying notes are an integral part of this press release. BILIBILI to Unaudited Financial Information(All amounts in thousands, except for share and per share data) For the Three Months Ended For the Six Months Ended June30, March31, June30, June30, June30, 2024 2025 2025 2024 2025 RMB RMB RMB RMB RMB Share-based compensation expenses included in: Cost of revenues 18,370 23,996 26,314 32,047 50,310 Sales and marketing expenses 13,361 16,417 19,800 25,921 36,217 General and administrative expenses 139,032 144,497 137,165 296,856 281,662 Research and development expenses 88,716 105,855 101,568 169,241 207,423 Total 259,479 290,765 284,847 524,065 575,612BILIBILI Condensed Consolidated Balance Sheets(All amounts in thousands, except for share and per share data) December 31, June 30, 2024 2025 RMB RMB Assets Current assets: Cash and cash equivalents 10,249,382 10,675,615 Time deposits 3,588,475 7,396,047 Restricted cash 50,000 50,800 Accounts receivable, net 1,226,875 1,083,544 Prepayments and other current assets 1,934,788 2,145,669 Short-term investments 2,706,535 4,219,143 Total current assets 19,756,055 25,570,818 Non-current assets: Property and equipment, net 589,227 608,268 Production cost, net 1,851,207 1,721,157 Intangible assets, net 3,201,012 3,019,348 Goodwill 2,725,130 2,725,130 Long-term investments, net 3,911,592 4,565,609 Other long-term assets 664,277 583,453 Total non-current assets 12,942,445 13,222,965 Total assets 32,698,500 38,793,783 Liabilities Current liabilities: Accounts payable 4,801,416 5,186,223 Salary and welfare payables 1,599,482 1,383,188 Taxes payable 428,932 415,028 Short-term loans and current portion of long-term debt 1,571,836 1,734,988 Deferred revenue 3,802,307 4,239,833 Accrued liabilities and other payables 2,558,830 3,055,058 Total current liabilities 14,762,803 16,014,318 Non-current liabilities: Long-term debt 3,264,153 8,088,858 Other long-term liabilities 567,631 534,849 Total non-current liabilities 3,831,784 8,623,707 Total liabilities 18,594,587 24,638,025 Total Bilibili Inc.'s shareholders' equity 14,108,397 14,162,576 Noncontrolling interests (4,484 ) (6,818 ) Total shareholders' equity 14,103,913 14,155,758 Total liabilities and shareholders' equity 32,698,500 38,793,783BILIBILI Selected Condensed Consolidated Cash Flows Data(All amounts in thousands, except for share and per share data) For the Three Months Ended For the Six Months Ended June30, March31, June30, June30, June30, 2024 2025 2025 2024 2025 RMB RMB RMB RMB RMB Net cash provided by operating activities 1,750,540 1,302,095 1,989,265 2,388,237 3,291,360BILIBILI Reconciliations of GAAP and Non-GAAP Results(All amounts in thousands, except for share and per share data) For the Three Months Ended For the Six Months Ended June30, March31, June30, June30, June30, 2024 2025 2025 2024 2025 RMB RMB RMB RMB RMB (Loss)/profit from operations (585,135 ) 15,008 251,612 (1,403,731 ) 266,620 Add: Share-based compensation expenses 259,479 290,765 284,847 524,065 575,612 Amortization expense related to intangible assets acquired through business acquisitions 41,776 36,692 36,692 83,552 73,384 Adjusted (loss)/profit from operations (283,880 ) 342,465 573,151 (796,114 ) 915,616 Net (loss)/profit (608,149 ) (10,677 ) 218,283 (1,372,780 ) 207,606 Add: Share-based compensation expenses 259,479 290,765 284,847 524,065 575,612 Amortization expense related to intangible assets acquired through business acquisitions 41,776 36,692 36,692 83,552 73,384 Income tax related to intangible assets acquired through business acquisitions (5,407 ) (4,136 ) (4,136 ) (10,814 ) (8,272 ) Loss on fair value change in investments in publicly traded companies 41,311 48,869 25,641 28,125 74,510 Loss on repurchase of convertible senior notes - - 2 20,980 2 Adjusted net (loss)/profit (270,990 ) 361,513 561,329 (726,872 ) 922,842 Net (profit)/loss attributable to noncontrolling interests (551 ) 1,575 719 15,535 2,294 Adjusted net (loss)/profit attributable to the Bilibili Inc.'s shareholders (271,541 ) 363,088 562,048 (711,337 ) 925,136 Adjusted net (loss)/profit per share, basic (0.65 ) 0.86 1.34 (1.71 ) 2.20 Adjusted net (loss)/profit per ADS, basic (0.65 ) 0.86 1.34 (1.71 ) 2.20 Adjusted net (loss)/profit per share, diluted (0.65 ) 0.85 1.29 (1.71 ) 2.15 Adjusted net (loss)/profit per ADS, diluted (0.65 ) 0.85 1.29 (1.71 ) 2.15 Weighted average number of ordinary shares, basic 416,287,273 420,086,397 419,443,582 415,780,807 419,763,214 Weighted average number of ADS, basic 416,287,273 420,086,397 419,443,582 415,780,807 419,763,214 Weighted average number of ordinary shares, diluted 416,287,273 425,602,954 437,370,780 415,780,807 431,601,628 Weighted average number of ADS, diluted 416,287,273 425,602,954 437,370,780 415,780,807 431,601,628
Yahoo
24 minutes ago
- Yahoo
BeeWeave Announces Launch of Equity Incentive Management System, Prepares for Nasdaq Listing
BEIJING, Aug. 21, 2025 /PRNewswire/ -- On August 20, Beijing Bee Weaving Network Technology Co., Ltd. ("Bee Weaving") announced the official launch of its Equity Incentive Management System, marking a key milestone in the company's long-term capitalization strategy. The initiative is designed to drive business expansion and technological innovation through a dual focus on talent incentives and capital deployment, strengthening Bee Weaving's leadership position in the biotech and AI sectors. Bee Weaving has also begun preparations for an RTO (Reverse Takeover) asset restructuring, with the goal of pursuing a Nasdaq Capital Market listing within three years. The company will adhere strictly to Nasdaq listing requirements, build a robust compliance and governance framework with leading advisory firms, and channel raised capital primarily into cell therapy R&D and market expansion across China and Southeast Asia. Global consultancy Vanguard Consulting (China) Group has expressed strong confidence in Bee Weaving's business model and growth outlook, committing to provide full-cycle advisory support throughout the Nasdaq listing process. Equity Incentives to Unlock Long-Term Value The equity incentive program is structured around "talent alignment, value sharing, and sustainable growth." Combining stock options and restricted shares, it will cover 30% of core employees and more than 100 strategic partners, directly linking incentives to market capitalization growth. The program is expected to attract top talent, accelerate technology breakthroughs, and provide momentum for global expansion. Bee Weaving anticipates increasing its global footprint through strategic acquisitions, integrations, and partnerships over the next three years. Capital + Talent: A Dual-Engine Growth Model By integrating equity incentives with capital market strategies, Bee Weaving aims to establish a closed-loop model of "capital empowerment, talent-driven performance, and sustainable growth." The company expects this system to foster innovation, attract top-tier talent in areas such as cell therapy and artificial intelligence, and strengthen its competitive position in emerging markets. Strategic Roadmap for the Next Three Years Bee Weaving's development plan focuses on three key priorities: Technology Leadership – Invest 40% of raised capital into core cell therapy R&D, targeting 100 new patents to solidify market leadership in biotechnology. Market Expansion – Drive vertical integration across the value chain through M&A and strategic consolidation, enhancing competitiveness. Globalization – Establish 20 overseas branches in Southeast Asia and Europe, expanding international market share. Building Investor Confidence & Sustainable Growth To ensure stability and transparency, Bee Weaving will implement the following measures: Financial Transparency – Annual performance disclosures and real-time reporting of revenue, net profit, and cash flow. Strategic Backing – Secured strategic lead investment from CIC Shengquan Fund, providing both financial resources and industry expertise. Risk Management – Flexible performance-based targets within the incentive plan to balance growth with risk control. Policy Alignment – Proactive engagement with government initiatives to capture policy-driven opportunities in biotech and AI. Chairman Wang Hailong's Statement "At Bee Weaving, we are committed to the principle of 'innovation-driven growth, talent as the foundation, and capital as a catalyst.' The launch of our equity incentive system represents a major step in aligning our team with long-term shareholder value. By combining world-class talent with smart capital deployment, we aim to transform technological leadership into market leadership. We look forward to working with global investors to write the next chapter of Bee Weaving's growth story." Media Contact: Zhao Gui LingContact No.:+86-18910400829Website： zhaoguiling@ View original content: SOURCE Bee Weaving Sign in to access your portfolio
